Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 542

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 542
---
 circumstances, on trade secrets to protect its technology. Kineta seeks to protect its proprietary technology and processes, and obtain and maintain ownership of certain technologies, in part, by confidentiality and invention assignment agreements with its employees, consultants, scientific advisors and contractors. Kineta also seeks to preserve the integrity and confidentiality of its data and trade secrets by maintaining physical security of its premises and physical and electronic security of its information technology systems.

Kineta’s patent strategy focuses on securing market exclusivity through a portfolio of patents and claim sets to ensure broad based protection for Kineta’s innovative technologies. Geographically, Kineta files patents in those countries that account for 90% of the revenue of the global pharmaceutical market as well as several additional markets due to their strategic importance, including the U.S., multiple EU countries, Japan, Korea, China, Hong Kong, India, Singapore, Switzerland (through the European Patent Organization), Russia, Canada and Mexico.

Kineta’s patent strategy includes filing for multiple claim sets that include both specific patent claims as well as broader based claims. This approach helps to protect the innovative science at Kineta and to protect its intellectual property. Kineta’s filing strategy includes filing for patent claims for (i) composition of matter, (ii) picture claims and sequences, (iii) product uses and indications, (iv) manufacturing and (v) pharmaceutical properties and characteristics.

<div align='center'>349</div>

The table below summarizes the high-level filing strategy of Kineta’s existing patent portfolio for its VISTA related assets:

|                                      |     | VISTA                          
 patents                        
 (KVA12123)                     |
| Patent Family                        |     | KVA-001                        |
| Composition of matter                |     | Y                              |
| Methods of Manufacturing             |     | Y                              |
| Sequences/Structure                  |     | Y                              |
| Indications                          |     | Y                              |
| Specification on use (mono or combo) |     | Y                              |
| Binding characteristics              |     | Y                              |
| Immune cell regulation               |     | Y                              |
| Physiologic properties               |     | Y                              |
| Discovery Candidates                 |     | To be added on a rolling basis |

Kineta strives to protect the proprietary technologies that it believes are important to its business, including by seeking, maintaining and defending patent rights, whether developed internally or in conjunction with or in-licensedfrom third parties. Kineta also relies on trade secrets relating to its monoclonal antibodies, know-how,continuing technological innovation